Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer-Reference-Cited by-同舟云学术

Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer

Published:2023-04-28 Issue:6 Volume:23 Page:593-600
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Nuvola Giacomo¹,Santoni Matteo²,Rizzo Mimma³,Rosellini Matteo¹,Mollica Veronica¹⁴,Rizzo Alessandro⁵,Marchetti Andrea¹,Battelli Nicola²,Massari Francesco¹⁴

Affiliation:

1. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia

2. Oncology Unit, Macerata Hospital, via Santa Lucia 2, Macerata, Italy

3. Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy

4. Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy

5. Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Istituto Tumori Giovanni Paolo II-Bari, Bari, Italy

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2023.2207827

Reference62 articles.

1. Understanding the Epidemiology, Natural History, and Key Pathways Involved in Prostate Cancer

2. A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

3. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

4. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

5. The mutational landscape of lethal castration-resistant prostate cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances and future perspectives in the therapeutics of prostate cancer;Experimental Hematology & Oncology;2023-09-22